Information Provided By: 
Fly News Breaks for March 12, 2018
SNY, REGN, ALNY
Mar 12, 2018 | 06:58 EDT
B. Riley FBR analyst Madhu Kumar believes this weekend's Odyssey Outcomes data from Regeneron (REGN) and Sanofi (SNY) undercuts the bear argument on Alnylam Pharmaceuticals (ALNY) that PCSK9 drugs do not demonstrate clinically meaningful mortality benefit. Further, the analyst believes Sanofi and Regeneron's lower Praluent pricing in high-risk patients will likely expand uptake of PCSK9 drugs in the cholesterol market. Kumar keeps a Buy rating on Alnylam with a $200 price target.
News For ALNY;REGN;SNY From the Last 2 Days
REGN
Apr 24, 2024 | 07:20 EDT
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
SNY
Apr 22, 2024 | 12:15 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
SNY
Apr 22, 2024 | 11:36 EDT
